SNCA and Parkinson disease: These findings suggest that interventions targeting SUMOylation activities, including the inhibition of the SUMO E1 enzyme, could be a therapeutic strategy to reduce α-synuclein-related pathology in Parkinsons disease (Dorval and Fraser 2006; Rott et al. 2017a, b; Vijayakumaran et al. 2019).